Rivaroxaban is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh B or C) due to increased risk of bleeding from reduced drug clearance.
Contraindicated in Child-Pugh B/C cirrhosis
Increased AUC of rivaroxaban by up to 2.3-fold in moderate impairment
Routine monitoring of INR or anti-Xa levels not reliable; Consult hepatology for bridging therapies.
Rivaroxaban undergoes hepatic metabolism primarily via CYP3A4/5 and CYP2J2 enzymes. In moderate to severe liver disease, hepatic function is impaired, leading to decreased metabolism and drug accumulation, which prolongs its anticoagulant effects and elevates bleeding risk.
Heightened risk of major bleeding events, including gastrointestinal, intracranial, or systemic hemorrhage, due to elevated plasma concentrations of rivaroxaban and potential coagulopathy associated with advanced liver disease.
Avoid rivaroxaban in patients with moderate (Child-Pugh B) or severe (Child-Pugh C) liver impairment. Consider alternative anticoagulants such as low-molecular-weight heparin or vitamin K antagonists in patients with less severe impairment after careful assessment; monitor liver function and bleeding parameters if use is unavoidable.
Was this helpful?
The content on SafeTo is for informational purposes only and does not constitute medical, veterinary, or professional advice. Always consult with a qualified professional for specific concerns.
Hot chocolate contains small amounts of tyramine and phenylethylamine, which can interact with MAOIs, potentially leading to a hypertensive crisis if consumed in large quantities, though the risk is generally low with moderate intake.
Kale, a vitamin K-rich leafy green, can interact with warfarin by potentially reducing its anticoagulant effects if intake is inconsistent or excessive.
Large amounts of lime juice may mildly interact with certain statins, similar to but less potent than grapefruit juice, by inhibiting drug metabolism and potentially increasing statin levels in the blood.
